Objective To develop new classification criteria for systemic lupus erythematosus (SLE)
jointly supported by the European League Against Rheumatism (EULAR) and the American …

Objective. To develop and perform an initial validation of a damage index for systemic lupus
erythematosus (SLE). Methods. A list of items considered to reflect damage in SLE was …

Psoriatic arthritis (PsA) has been defined as a unique inflammatory arthritis associated with
psoriasis. Its exact prevalence is unknown, but estimates vary from 0.3% to 1% of the …

Objective. To standardize outcome measures in systemic lupus erythematosus (SLE). Three
indices were identified which could adequately describe outcome (disease activity, damage …

Abstract Objective The Systemic Lupus International Collaborating Clinics (SLICC) group
revised and validated the American College of Rheumatology (ACR) systemic lupus …

OBJECTIVE: To describe the Systemic Lupus Erythematosus Disease Activity Index 2000
(SLEDAI-2K), a modification of SLEDAI to reflect persistent, active disease in those …

A review of the literature suggests there are two major aspects of responsiveness. We define
the first as “internal responsiveness,” which characterizes the ability of a measure to change …

Objective To examine mortality rates in the largest systemic lupus erythematosus (SLE)
cohort ever assembled. Methods Our sample was a multisite international SLE cohort (23 …

Objective. To compare the accuracy of existing classification criteria for the diagnosis of
psoriatic arthritis (PsA) and to construct new criteria from observed data. Methods. Data were …

Objective Adalimumab, a fully human, anti–tumor necrosis factor monoclonal antibody, was
evaluated for its safety and efficacy compared with placebo in the treatment of active …